Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP

Thehuman internal dosimetry of the radionuclidic impurities of samarium-153 in a new bone-seeking radiopharmaceutical, (153)Sm-1,4,7,10tetraazacyclododecanetetramethylenephosponic acid ((153)Sm-DOTMP), has been estimated from preclinical data. The effective dose from the impurities in lower-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Wendt, Richard E., Ketring, Alan R., Frank, R. Keith, Simón, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896376/
https://www.ncbi.nlm.nih.gov/pubmed/35452906
http://dx.doi.org/10.1016/j.apradiso.2022.110246
_version_ 1784882042938327040
author Wendt, Richard E.
Ketring, Alan R.
Frank, R. Keith
Simón, Jaime
author_facet Wendt, Richard E.
Ketring, Alan R.
Frank, R. Keith
Simón, Jaime
author_sort Wendt, Richard E.
collection PubMed
description Thehuman internal dosimetry of the radionuclidic impurities of samarium-153 in a new bone-seeking radiopharmaceutical, (153)Sm-1,4,7,10tetraazacyclododecanetetramethylenephosponic acid ((153)Sm-DOTMP), has been estimated from preclinical data. The effective dose from the impurities in lower-specific-activity (153)Sm is less than 17% of the effective dose from pure Sm-153. It has a background-equivalent radiation time for a dosage of 37 MBq/kg of less than one-half year.
format Online
Article
Text
id pubmed-9896376
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-98963762023-02-03 Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP Wendt, Richard E. Ketring, Alan R. Frank, R. Keith Simón, Jaime Appl Radiat Isot Article Thehuman internal dosimetry of the radionuclidic impurities of samarium-153 in a new bone-seeking radiopharmaceutical, (153)Sm-1,4,7,10tetraazacyclododecanetetramethylenephosponic acid ((153)Sm-DOTMP), has been estimated from preclinical data. The effective dose from the impurities in lower-specific-activity (153)Sm is less than 17% of the effective dose from pure Sm-153. It has a background-equivalent radiation time for a dosage of 37 MBq/kg of less than one-half year. 2022-07 2022-04-14 /pmc/articles/PMC9896376/ /pubmed/35452906 http://dx.doi.org/10.1016/j.apradiso.2022.110246 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Wendt, Richard E.
Ketring, Alan R.
Frank, R. Keith
Simón, Jaime
Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP
title Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP
title_full Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP
title_fullStr Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP
title_full_unstemmed Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP
title_short Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP
title_sort dosimetric implications of the potential radionuclidic impurities in (153)sm-dotmp
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896376/
https://www.ncbi.nlm.nih.gov/pubmed/35452906
http://dx.doi.org/10.1016/j.apradiso.2022.110246
work_keys_str_mv AT wendtricharde dosimetricimplicationsofthepotentialradionuclidicimpuritiesin153smdotmp
AT ketringalanr dosimetricimplicationsofthepotentialradionuclidicimpuritiesin153smdotmp
AT frankrkeith dosimetricimplicationsofthepotentialradionuclidicimpuritiesin153smdotmp
AT simonjaime dosimetricimplicationsofthepotentialradionuclidicimpuritiesin153smdotmp

Ejemplares similares